Artelo Biosciences, Inc. Stock

ARTL

US04301G8050

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 22/09/2026 +04			5-day change	1st Jan Change
4.100 ^USD	+4.06%		-15.81%	-87.55%

09-16	Artelo Biosciences, Inc. Announces ART27.13 Achieves Weight Loss Comparable To Semaglutide And Doubles Weight Loss In Combination In Nonclinical Obesity Model	CI
08-20	Artelo Biosciences Secures Notice Of Allowance In Japan For Patent Claims For Intended Commercial Formulation Of ART27.13	CI

Valuation: Artelo Biosciences, Inc.

Market Cap	2.09M 1.83M 1.72M 1.57M 2.94M 201M 2.94M 20.59M 7.93M 102M 7.86M 7.69M 330M	P/E 2024	-0.35x	P/E 2025	-0.1x
Enterprise Value	2.17M 1.89M 1.78M 1.62M 3.04M 208M 3.05M 21.35M 8.23M 106M 8.16M 7.98M 342M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.89%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Artelo Biosciences, Inc.

NasdaqUSD

Markets		Quality
Nasdaq	ARTL	Delayed
CBOE	ARTL	Real-time

Dynamic Chart

Latest news: Artelo Biosciences, Inc.

09-16	Artelo Biosciences, Inc. Announces ART27.13 Achieves Weight Loss Comparable To Semaglutide And Doubles Weight Loss In Combination In Nonclinical Obesity Model	CI
08-20	Artelo Biosciences Secures Notice Of Allowance In Japan For Patent Claims For Intended Commercial Formulation Of ART27.13	CI
08-17	Artelo Biosciences Receives Notice Of Allowance For U.S. Patent Covering Intended Commercial Formulation Of ART27.13	CI
08-13	Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-10	Artelo Biosciences, Inc. Enrolls First Patient in Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma	CI
07-16	Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions	CI
07-16	Artelo Biosciences Says New Data Shows ART26.12 Reduces Osteoarthritis Pain	MT
07-13	Artelo Says ART27.13 Decreases Neuropathic Pain-linked Behaviors in Animals Treated With Paclitaxel	MT
07-13	Artelo Biosciences Announces Positive Results With ART27.13 In A Nonclinical Model Of Paclitaxel-Induced Peripheral Neuropathy	CI
07-01	Artelo Biosciences Announces New Data Supporting ART26.12 As A Potential First-In-Class Therapy For Chronic Pain Associated With Spinal Cord Injury	CI
06-30	Artelo Biosciences Presents Evidence for A Common Lipid-Signaling Link Across Multiple Potential Indications for Its Fabp5 Inhibitor Platform At Icrs 2026	CI
06-29	Artelo Biosciences Presents Clinical And Biomarker Data Supportive Of The Development Of ART26.12 And Follow-On FABP5 Inhibitors	CI
06-10	Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated With Clinical Development Success	CI

More news

Analysts' recommendations: Artelo Biosciences, Inc.

11-19	Maxim Downgrades Artelo Biosciences to Hold From Buy	MT
15/10/25	Artelo Biosciences, Inc. Announces Expanded Clinical Data to Be Presented on Both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit	CI
12/08/22	HC Wainwright Lowers Price Target for Artelo Biosciences to $55 From $60, Maintains Buy Rating	MT
01/11/21	HC Wainwright Starts Artelo Biosciences at Buy With $4 Price Target	MT
12/02/21	Artelo Biosciences : Ladenburg Thalmann Starts Artelo Biosciences at Buy with $7 Price Target	MT

More recommendations

Press Releases: Artelo Biosciences, Inc.

09-16	Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity	AQ
09-08	Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-27	Artelo Biosciences Announces Reverse Stock Split	AQ
08-20	Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13	AQ
08-17	Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies	AQ

More press releases

Managers and Directors: Artelo Biosciences, Inc.

Manager	Title	Age	Since
Gregory Gorgas CEO	Chief Executive Officer	63	03/04/2017
Mark Spring DFI	Director of Finance/CFO	67	01/12/2024
Andy Yates CTO	Chief Tech/Sci/R&D Officer	-	01/01/2021

Director	Title	Age	Since
Gregory Gorgas BRD	Director/Board Member	63	03/04/2017
Connie Matsui CHM	Chairman	72	02/05/2017
Steven Kelly BRD	Director/Board Member	61	02/05/2017

More insiders

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
21/09/26	$4.100	+4.06%	73,081
18/09/26	$3.940	-0.76%	29,661
17/09/26	$3.970	+5.87%	125,237
16/09/26	$3.750	-29.78%	277,961
15/09/26	$5.340	+9.65%	91,458

Delayed Quote Nasdaq

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stocks
ARTL Stock

-40%: Exceptional extension

SEIZE THE OFFER!

1 day	+4.06%
1 week	-15.81%
Current month	-35.53%
1 month	-34.17%
3 months	-63.84%
6 months	-94.28%
Current year	-87.55%

1 week	3.45	4.9
1 month	3.45	6.8
Current year	3.45	179.19
1 year	3.45	179.19
3 years	3.45	772.2
5 years	3.45	3,207.6
10 years	3.45	52,487.93

Date	Insider	Type	Main position	Quantity	% Market Cap.
17/07/26	Steven Kelly	Free	Director	136	0.0039%
17/07/26	Tamara Favorito	Free	Director	136	0.0039%
17/07/26	Robert Emanuele	Free	Director	136	0.0039%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARTELO BIOSCIENCES, INC.	+4.06%	-15.81%	-97.30%	-98.30%	2.01M
WUXI APPTEC CO., LTD.	+4.98%	+5.73%	+54.45%	+113.83%	70.88B
ARGENX SE	-0.39%	+0.02%	+38.84%	+83.28%	62.49B
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	+7.68%	+32.24%	+24.27%	26.34B
INSMED INCORPORATED	+0.83%	-3.43%	-16.41%	+359.38%	26.21B
BIONTECH SE	+2.02%	-0.87%	+1.85%	-7.92%	24.13B
GENMAB A/S	0.00%	+6.81%	+25.03%	-11.44%	20.72B
PHARMAESSENTIA CORPORATION	-2.54%	-3.36%	+149.64%	+324.48%	15.69B
EXELIXIS, INC.	-1.95%	+1.80%	+42.69%	+165.15%	14.46B
SUMMIT THERAPEUTICS INC.	-5.32%	-8.25%	-10.53%	+823.50%	14.24B
Average	+0.17%	-0.86%	+22.05%	+177.62%	27.52B
Weighted average by Cap.	+0.93%	+2.17%	+36.65%	+153.03%

	2024	2025
Net sales	-	-
Net income	-9.83M -8.57M -8.07M -7.35M -13.78M -941M -13.79M -96.63M -37.25M -480M -36.91M -36.09M -1.55B	-12.88M -11.23M -10.58M -9.63M -18.06M -1.23B -18.08M -127M -48.82M -629M -48.38M -47.31M -2.03B
Net Debt	-2.23M -1.95M -1.83M -1.67M -3.13M -214M -3.14M -21.97M -8.47M -109M -8.39M -8.21M -352M	78K 68.01K 64.05K 58.33K 109K 7.47M 110K 767K 296K 3.81M 293K 287K 12.28M

Artelo Biosciences, Inc. Stock

Stocks

ARTL

US04301G8050

Biotechnology & Medical Research

Valuation: Artelo Biosciences, Inc.

Chart: Artelo Biosciences, Inc.

Latest news: Artelo Biosciences, Inc.

Analysts' recommendations: Artelo Biosciences, Inc.

Press Releases: Artelo Biosciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Artelo Biosciences, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise